Goals: International guidelines support the use of the Oncotype DX derived Recurrence Score (RS) to provide additional prognostic and predictive information in early breast cancer but experience in the UK is limited. In our prospective study we evaluate this test for the NHS and its impact on costs (subject of a separate abstract) and treatment recommendations by UK oncologists.
Goals: International guidelines support the use of the Oncotype DX derived Recurrence Score (RS) to provide additional prognostic and predictive information in early breast cancer but experience in the UK is limited. In our prospective study we evaluate this test for the NHS and its impact on costs (subject of a separate abstract) and treatment recommendations by UK oncologists.
Methods: 150 tests were made available to consecutive patients with ER+, pN0 or pN1mic early breast cancer who had no contraindication to adjuvant chemotherapy (CT) and who would accept chemotherapy if recommended. CT recommendations of oncologists based on Adjuvant! Online figures were recorded at an initial consultation and again after a second consultation once the RS was available.
Results: Analysis is based on 142 patients. (150 tests performed, 3 failed to give a result, 3 repeated tests giving a result on the second block, one bilateral and one test stopped because the patient withdrew from the study). Initial treatment recommendations changed in 38 (26.8%) cases. Of the patients initially recommended CT + HT (total 57 patients), 26 (45.6%) patients were spared chemotherapy after review of the RS. Of the 85 patients initially recommended HT only (total 85 patients), 12 (14.1%) were changed to HT+CT. 
